Episode 4: Should You Take a Statin? ( Cardiovascular Disease: Part 4) Podcast By cover art

Episode 4: Should You Take a Statin? ( Cardiovascular Disease: Part 4)

Episode 4: Should You Take a Statin? ( Cardiovascular Disease: Part 4)

Listen for free

View show details

About this listen

 Episode 4: Should You Take a Statin? (Cardiovascular Series: Part 4) In this episode, we dive deep into statins—the most widely prescribed cholesterol-lowering drugs—and ask the hard questions: Do they really prevent heart disease? Are the benefits worth the risks? What does the data really say? Topics include: The history of statins and how they were discoveredThe role of LDL in healing vs. harmRisks: muscle pain, cognitive issues, diabetes, mitochondrial dysfunction, and moreBenefit vs. risk by ASCVD scoreMajor trials like JUPITER, FOURIER, and the CTT meta-analysisThe role of PCSK9 inhibitors and anti-inflammatory effectsWhy relative risk reduction numbers can be misleadingHow to make an informed, individualized decision about statins🔢 Start Here: ASCVD Risk Calculator Use this tool during the episode to estimate your 10-year cardiovascular risk. https://tools.acc.org/ascvd-risk-estimator-plus/#!/calculate/estimate/ 📚 References & Resources Statins for Primary Prevention – NNT Review Summary of evidence on statins for people without prior heart disease. ASCVD Risk Calculator Estimate your 10-year cardiovascular risk using standard clinical inputs. CTT Collaboration – NEJM 2017 PCSK9 Trial (FOURIER) Evaluated evolocumab’s impact on major cardiovascular outcomes. Statins and Myopathy – PRIMO Study Real-world observational study showing 10.5% statin-associated muscle problems. Statins and Mitochondrial Dysfunction Statins impair CoQ10 and heme synthesis, disrupting cellular energy production. Therapeutics Initiative – Statins for Primary Prevention Independent review finding no mortality benefit for low-risk individuals. Dr. Kumar’s Breakdown – JUPITER Trial and Inflammation How rosuvastatin lowered CRP and what that might mean. ASCVD Risk Calculator Overestimation Real-world data shows the tool often inflates predicted risk. Statins and Cognition – Pilot Withdrawal/Rechallenge Study Cognitive function improved in dementia patients after statin withdrawal. LDL Lowering vs. CVD Risk – Regression Model Critique by Ravnskov Analysis showing how excluding trials distorts the LDL-CVD link. Statin Use and Mortality Trends in Europe Statin utilization did not consistently correlate with mortality reduction. JUPITER Trial Results Reported a 44% relative risk reduction but only 1.2% absolute difference. CTT Meta-Analysis – 2012 Lancet Paper Meta-analysis of 27 statin trials, stratified by baseline risk. JAMA Meta-Analysis – Statins in Primary Prevention Found no mortality benefit from statins in low-risk patients. Niacin and Statin Alternatives – JNRBM Review Survey of other lipid-lowering therapies and their efficacy. NNT Review – Statins for Low-Risk Individuals Found minimal benefit and higher risk of side effects. BMJ Open – Industry Bias in Statin Trials Analysis of how pharmaceutical sponsorship shapes outcomes. Dr. Kumar’s Review – Statin Effectiveness and Safety A blog summary aligning with this podcast episode. Dr. Kumar’s Blog – Cognitive Side Effects of Statins Observational insight into brain fog and memory decline. Mitochondrial Effects of Statins – Golomb 2006 Review Review of mitochondrial dysfunction and muscle symptoms from statins. 🙏 Support the Show If you found this episode valuable, help us spread the word:Subscribe to the podcast on your favorite platformRate & review the show to boost visibilityShare this episode with friends, family, or colleagues who care about heart healthVisit: DrKumarDiscovery.com for blog posts, show notes, and more episodesThanks for joining me on this journey to cut through the noise and uncover the truth in medicine. I’ll see you in the next episode.
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
No reviews yet